GenSci048

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

EndometriosisUveitisConnective Tissue Disease

57 competitors in Endometriosis

#DrugCompanyPhaseTrials

1

Danocrine

Sanofi

Approved

52

Bayer Aspirin

Bayer

Approved

23

IC-Green

PProvepharm SAS

Approved

44

Estrace

Novo Nordisk

Approved

—5

Ketalar

AAultman Health Foundation

Approved

26

Catapres

Boehringer Ingelheim

Approved

17

Lipitor

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

18

Jadelle

IItalian Network for Tumor Biotherapy Foundation

Approved

19

Flagyl

DDePuy Orthopaedics

Approved

110

Trelstar

OOncoVerity, Inc.

Approved

1Show 36 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Endometriosis1 trial

A Phase IIa Clinical Study to Assess the Efficacy and Safety of GenSci048 in Patients With Moderate to Severe Endometriosis-Associated Pain

Recruiting·Changchun GeneScience Pharmaceutical Co., Ltd.·Phase 2·NCT06963177·200 enrolled

Connective Tissue Disease1 trial

A Randomized, Double-blind, Placebo-controlled Phase II Clinical Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetic Profile of Genakumab Injection in Patients With Connective Tissue Disease-associated Interstitial Lung Disease

Recruiting·Changchun GeneScience Pharmaceutical Co., Ltd.·Phase 2·NCT06189495·30 enrolled

Uveitis1 trial

A Phase II Clinical Study to Assess the Efficacy and Safety of GenSci048 in Subjects With Active Non-infectious Uveitis.

Recruiting·Changchun GeneScience Pharmaceutical Co., Ltd.·Phase 2·NCT07547995·74 enrolled

Details

Drug Info

Related News